One of the advantages in genetically engineering human insulin was scientists already knew the protein's amino acid sequence
No, frequent urination is not listed as a common side effect in FDA prescribing information for GLP-1 receptor agonists
Its labeled indications are glycemic control in adults with type 2 diabetes, reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduction of the risk of kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease
Research remains exploratory, focusing on neural communication, pathway interaction, and system-wide regulatory responses rather than clinical or physiological outcomes
Mann DM, Jones D, Prinja D, Purkiss MS